{"id":2329,"date":"2022-04-28T06:53:06","date_gmt":"2022-04-28T06:53:06","guid":{"rendered":"https:\/\/aspree.org\/usa\/?p=2329"},"modified":"2022-06-20T08:23:53","modified_gmt":"2022-06-20T08:23:53","slug":"findings-continue-to-impact-international-aspirin-guidelines","status":"publish","type":"post","link":"https:\/\/aspree.org\/usa\/findings-continue-to-impact-international-aspirin-guidelines\/","title":{"rendered":"Findings continue to impact aspirin guidelines"},"content":{"rendered":"

U.S. medical expert group latest to cite ASPREE results in guidelines<\/h2>\n

Major findings from the ASPREE trial<\/a><\/span> have been adopted into influential US Preventive Services Taskforce (USPSTF) new medical aspirin guidelines.<\/p>\n

The USPSTF recently announced a new recommendation against older adults, aged over 60, starting low-aspirin to prevent cardiovascular disease (CVD; i.e. diseases of the heart and blood vessels).<\/p>\n

ASPREE Principal Investigator in the U.S., Dr. Anne Murray, said USPSTF recommendations were based on a review of global scientific evidence into the benefits and risks of aspirin use.<\/p>\n

\"Photo

Above: Principal Investigator to the ASPREE Trial in the U.S., Dr Anne Murray.<\/em><\/p><\/div>\n

\u201cThe new USPSTF aspirin guidelines for healthy older adults now closely reflect the findings of ASPREE, \u201c said Dr. Murray.<\/p>\n

ASPREE, a world-first aspirin trial in 19,114 healthy older adults in Australia and the US, released its findings<\/span><\/a> to international acclaim in 2018.<\/p>\n

Shortly after, the American College of Cardiology and American Heart Association incorporated ASPREE findings into revised primary prevention aspirin guidelines<\/span><\/a>, recommending against aspirin for primary prevention* in adults aged 70 and over.<\/p>\n

Guidelines are used by doctors and patients to manage health care.<\/p>\n

A statement<\/span><\/a> on the USPSTF website explained the taskforce\u2019s new recommendation: \u201cThe magnitude of the harms (of aspirin) is small overall but increases in older age groups, particularly in adults older than 60 years\u2026. The USPSTF concludes with moderate certainty that initiating aspirin use for the primary prevention of CVD events in adults 60 years or older has no net benefit.\u201d<\/p>\n

Cardiovascular disease is a leading cause of death in Australia and the US.<\/p>\n

The USPSTF did not recommend aspirin to prevent colorectal cancer, citing the need for more evidence.<\/p>\n

Dr. Murray said the current lack of evidence for cancer highlights the importance of ASPREE-XT, ASPREE\u2019s follow up study, that will examine the effect of aspirin on colorectal cancer in older adults over the longer term.<\/p>\n

Dr. Murray added that the new USPSTF aspirin recommendations only apply to people who do not have a medical reason to take aspirin.
\n\u201cThe use of low-dose aspirin for secondary prevention, such as after a heart attack, should continue,\u201d said Dr. Murray. \u201cSpeak to your primary care physician for individual advice before starting or stopping daily low-dose aspirin.\u201d<\/p>\n

*Primary prevention is a therapy or treatment to prevent the first episode of a disease or health event from occurring, such as a heart attack or stroke.<\/em><\/p>\n

 <\/p>\n

———————————————————————————————————————————————————–<\/p>\n

Further reading:<\/strong><\/p>\n

Lay summary:<\/p>\n

Jin J. Use of Aspirin to Prevent Cardiovascular Disease.\u00a0JAMA.<\/em>\u00a02022;327(16):1624. doi:10.1001\/jama.2022.5564<\/a><\/p>\n

Papers:<\/p>\n

US Preventive Services Task Force. Aspirin Use to Prevent Cardiovascular Disease:\u00a0US Preventive Services Task Force Recommendation Statement.\u00a0JAMA.\u00a02022;327(16):1577\u20131584. doi:10.1001\/jama.2022.4983<\/a><\/p>\n

Guirguis-Blake JM, Evans CV, Perdue LA, Bean SI, Senger CA. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022;327(16):1585\u20131597. doi:10.1001\/jama.2022.3337<\/a><\/p>\n

Dehmer SP, O\u2019Keefe LR, Evans CV, Guirguis-Blake JM, Perdue LA, Maciosek MV. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer:\u00a0<\/span>Updated Modeling Study for the US Preventive Services Task Force<\/span>.\u00a0JAMA.<\/em>\u00a02022;327(16):1598\u20131607. doi:10.1001\/jama.2022.3385<\/a><\/p>\n

Editorial:<\/p>\n

Mora S, Shufelt CL, Manson JE. Whom to Treat for Primary Prevention of Atherosclerotic Cardiovascular Disease:\u00a0The Aspirin Dilemma.\u00a0JAMA Intern Med.\u00a0Published online April 26, 2022. doi:10.1001\/jamainternmed.2022.1365<\/a><\/p>\n

Brett AS. Should Patients Take Aspirin for Primary Cardiovascular Prevention? Updated Recommendations From the US Preventive Services Task Force. JAMA. 2022;327(16):1552\u20131554. doi:10.1001\/jama.2022.2460<\/a><\/p>\n

Lloyd-Jones DM. USPSTF Report on Aspirin for Primary Prevention.\u00a0JAMA Cardiol.<\/em>\u00a0Published online April 26, 2022. doi:10.1001\/jamacardio.2022.0935<\/a><\/p>\n

Berger JS. Aspirin for Primary Prevention\u2014Time to Rethink Our Approach.\u00a0JAMA Netw Open.<\/em>\u00a02022;5(4):e2210144. doi:10.1001\/jamanetworkopen.2022.10144<\/a><\/p>\n

Author Interview:\u00a0 USPSTF Recommendation: Aspirin Use for Cardiovascular Disease<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

U.S. medical expert group latest to cite ASPREE results in guidelines Major findings from the ASPREE trial have been adopted into influential US Preventive Services Taskforce (USPSTF) new medical aspirin guidelines. The USPSTF recently announced a new recommendation against older adults, aged over 60, starting low-aspirin to prevent cardiovascular disease (CVD; i.e. diseases of the […]<\/p>\n","protected":false},"author":9,"featured_media":1714,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[13,15,16],"tags":[33,49,45,46,47],"_links":{"self":[{"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/posts\/2329"}],"collection":[{"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/comments?post=2329"}],"version-history":[{"count":7,"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/posts\/2329\/revisions"}],"predecessor-version":[{"id":2355,"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/posts\/2329\/revisions\/2355"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/media\/1714"}],"wp:attachment":[{"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/media?parent=2329"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/categories?post=2329"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aspree.org\/usa\/wp-json\/wp\/v2\/tags?post=2329"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}